Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand

被引：0
|
作者：
Unchalee Permsuwan
Nathorn Chaiyakunapruk
Piyameth Dilokthornsakul
Kednapa Thavorn
Surasak Saokaew
机构：
[1] Chiang Mai University,Faculty of Pharmacy
[2] School of Pharmacy,Center of Pharmaceutical Outcomes Research (CPOR), Faculty of Pharmaceutical Sciences
[3] Monash University Malaysia,Faculty of Medicine
[4] Naresuan University,School of Pharmaceutical Sciences, Center of Health Outcomes Research and Therapeutic Safety (COHORTS)
[5] School of Population Health,undefined
[6] University of Queensland,undefined
[7] School of Pharmacy,undefined
[8] University of Wisconsin-Madison,undefined
[9] Ottawa Hospital Research Institute,undefined
[10] The Ottawa Hospital,undefined
[11] School of Epidemiology,undefined
[12] Public Health and Preventive Medicine,undefined
[13] University of Ottawa,undefined
[14] Institute of Clinical and Evaluative Sciences,undefined
[15] University of Phayao,undefined
来源：
Applied Health Economics and Health Policy | 2016年 / 14卷
关键词：
Insulin Glargine; Weighted Mean Difference; Thai Population; Social Security Scheme; CORE Diabetes Model;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：281 / 292
页数：11
相关论文
共 50 条
  • [1] Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand
    Permsuwan, Unchalee
    Chaiyakunapruk, Nathorn
    Dilokthornsakul, Piyameth
    Thavorn, Kednapa
    Saokaew, Surasak
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (03) : 281 - 292
  • [2] The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics
    Levin, P.
    [J]. DIABETES OBESITY & METABOLISM, 2008, 10 : 66 - 75
  • [3] Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy
    Smith, Jennifer G.
    Manuck, Tracy A.
    White, Jenifer
    Merrill, David C.
    [J]. AMERICAN JOURNAL OF PERINATOLOGY, 2009, 26 (01) : 57 - 62
  • [4] SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN
    Ramirez de Arellano, A.
    Morales, C.
    De Luis, D.
    Ferrario, M. G.
    Lizan, L.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
  • [5] An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Nikolajsen, Annie
    Shafie, Asrul Akmal
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 263 - 272
  • [6] LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN SWEDEN
    Valentine, W. J.
    Lammert, M.
    Aagren, M.
    Gschwend, M. H.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A503 - A503
  • [7] Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
    Pollock, Richard F.
    Chubb, Barrie
    Valentine, William J.
    Heller, Simon
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2018, 11 : 217 - 226
  • [8] Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden
    Valentine, William J.
    Aagren, Mark
    Haglund, Mattias
    Ericsson, Asa
    Gschwend, Manuela H.
    [J]. SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2011, 39 (01) : 79 - 87
  • [9] SHORT AND LONG-TERM COST-EFFECTIVENESS OF SWITCHING THERAPY FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PEOPLE WITH TYPE 2 DIABETES
    Malek, R.
    Galvez, G. G.
    Hammerby, E.
    Nikolajsen, A.
    Henriksen, O.
    Andersen, M. F. B.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A690 - A690
  • [10] COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE AND VERSUS BIPHASIC INSULIN ASPART FOR THE TREATMENT OF TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM HEALTH ECONOMIC ANALYSIS
    Palmer, J. L.
    Pinto, C. G.
    Duarte, R.
    Miguel, L.
    Gregor, Z.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
12345